Here are the 424B prospectus supplements from Longevity Health Holdings WT (XAGEW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow XAGEW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAGEW filings page.
Longevity Health Holdings, Inc. (XAGE) added a new disclosure to its existing prospectus for 44,382 shares of common stock by incorporating a recent financing in which it issued a 10% Senior Secured Convertible Note with an original principal amount of $416,667 to Puritan Partners LLC for $375,000 in cash proceeds. The note matures on February 29, 2028, pays 10% annual interest in cash monthly, and is convertible into common stock at a fixed price of $0.50 per share, or, at the holder’s election when the market trades lower, at 80% of the average closing prices over the prior five trading days.
The company states that, assuming conversion of all notes and accrued interest through maturity based on recent trading prices, it may need to issue up to 2,690,455 shares of common stock, subject to a 4.99% beneficial ownership cap (increasable to 9.99% on notice). The note is secured by a first‑priority lien on substantially all assets of Longevity Health and its subsidiaries, which also provide guarantees and an Affidavit of Confession of Judgment, and the company agrees to register the resale of conversion shares and to reserve at least four times the maximum conversion shares from its authorized but unissued stock.
Longevity Health Holdings, Inc. (XAGEW) updates its June 5, 2024 resale prospectus covering 44,382 shares of common stock by incorporating a new Form 8-K describing recent financing activity.
On August 31, 2026, the company issued a 10% Senior Secured Convertible Note with an original principal amount of $416,667 (10% original issue discount) to Puritan Partners LLC for a purchase price of $375,000, maturing on February 29, 2028. The note is convertible at a fixed price of $0.50 per share, or at the holder’s election at an alternative price equal to 80% of the average closing prices over the five trading days before conversion, subject to a 4.99% (up to 9.99%) Beneficial Ownership Limitation. The company discloses it may need to issue up to 2,690,455 shares upon conversion of principal and interest on the notes and has agreed to reserve at least four times the maximum shares required for conversion.
The note is secured by a first‑priority lien on substantially all assets of the company and its subsidiaries, which have guaranteed the obligations, and is subject to default premiums of 115% (or 125% for certain defaults) of outstanding principal plus accrued amounts. The securities were sold in a private placement relying on Section 4(a)(2) and Rule 506 of Regulation D, with the company agreeing to seek registration for resale of the conversion shares.